EXPRESS: Reasons for Refusing Parenteral Therapy: A Qualitative Study of Patients with Pulmonary Arterial Hypertension

While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously (IV)is recommended for pulmonary arterial hypertension (PAH) patients with severe or rapidly developin...